Gefitinib (‘Iressa’, ZD1839) and new epidermal growth factor receptor inhibitors

The epidermal growth factor receptor (EGFR) is a promising target for cancer therapy and a number of EGFR-targeted agents have been developed. Those most advanced in development are the EGFR tyrosine kinase inhibitors gefitinib (‘Iressa’, ZD1839) and erlotinib (‘Tarceva’, OSI-774), and the monoclona...

Descripción completa

Detalles Bibliográficos
Autores principales: Blackledge, G, Averbuch, S
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2004
Materias:
Minireview
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409596/
https://www.ncbi.nlm.nih.gov/pubmed/14760365
http://dx.doi.org/10.1038/sj.bjc.6601550

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409596/
https://www.ncbi.nlm.nih.gov/pubmed/14760365
http://dx.doi.org/10.1038/sj.bjc.6601550

Ejemplares similares